125 related articles for article (PubMed ID: 37681328)
1. Application of Dynamic Enhanced Magnetic Resonance Imaging Texture Analysis Combined with ADCs in Predicting Pelvic Lymph Metastasis of Prostate Cancer.
Yao L; Ding J; Li X; Yang J; Chen Z; Jia C; Duan Q
Arch Esp Urol; 2023 Aug; 76(6):383-388. PubMed ID: 37681328
[TBL] [Abstract][Full Text] [Related]
2. Application evaluation of DCE-MRI combined with quantitative analysis of DWI for the diagnosis of prostate cancer.
Ma XZ; Lv K; Sheng JL; Yu YX; Pang PP; Xu MS; Wang SW
Oncol Lett; 2019 Mar; 17(3):3077-3084. PubMed ID: 30867737
[TBL] [Abstract][Full Text] [Related]
3. The Assessment of Prostate Cancer Aggressiveness Using a Combination of Quantitative Diffusion-Weighted Imaging and Dynamic Contrast-Enhanced Magnetic Resonance Imaging.
Zhu G; Luo J; Ouyang Z; Cheng Z; Deng Y; Guan Y; Du G; Zhao F
Cancer Manag Res; 2021; 13():5287-5295. PubMed ID: 34239327
[TBL] [Abstract][Full Text] [Related]
4. Distinguishing T1-2 and T3a tumors of rectal cancer with texture analysis and functional MRI parameters.
Sun D; Wu X; Wang L; Li G; Huang J; Li Y
Diagn Interv Radiol; 2022 May; 28(3):200-207. PubMed ID: 35748201
[TBL] [Abstract][Full Text] [Related]
5. Dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging in the activity staging of terminal ileum Crohn's disease.
Wu YC; Xiao ZB; Lin XH; Zheng XY; Cao DR; Zhang ZS
World J Gastroenterol; 2020 Oct; 26(39):6057-6073. PubMed ID: 33132655
[TBL] [Abstract][Full Text] [Related]
6. Differentiation of bone metastases from prostate cancer and benign red marrow depositions of the pelvic bone with multiparametric MRI.
Park S; Park JG; Jun S; Kim H; Kim TS; Kang H
Magn Reson Imaging; 2020 Nov; 73():118-124. PubMed ID: 32860869
[TBL] [Abstract][Full Text] [Related]
7. The value of multimodal magnetic resonance imaging in breast cancer and its correlation with pathological features and prognosis.
Luo Q; Yang L; Zhou X
Eur Rev Med Pharmacol Sci; 2023 Sep; 27(18):8397-8403. PubMed ID: 37782156
[TBL] [Abstract][Full Text] [Related]
8. [The value of DISCO and MUSE-DWI combined with prostate specific antigen density in the diagnosis and risk stratification of prostate cancer].
Chen ZQ; Zhang D; Wang Z; Song N; Ma AL; Zhang SR; Cai L
Zhonghua Yi Xue Za Zhi; 2023 May; 103(19):1461-1468. PubMed ID: 37198108
[No Abstract] [Full Text] [Related]
9. Early prediction of pathological complete response to neoadjuvant chemotherapy combining DCE-MRI and apparent diffusion coefficient values in breast Cancer.
Liang X; Chen X; Yang Z; Liao Y; Wang M; Li Y; Fan W; Dai Z; Zhang Y
BMC Cancer; 2022 Dec; 22(1):1250. PubMed ID: 36460972
[TBL] [Abstract][Full Text] [Related]
10. Prediction of the response of ocular adnexal lymphoma to chemotherapy using combined pretreatment dynamic contrast-enhanced and diffusion-weighted MRI.
Guo P; Liu Z; Yan F; Wang J; Wei L; Lv H; Wang Z; Xian J
Acta Radiol; 2016 Dec; 57(12):1490-1496. PubMed ID: 27012277
[TBL] [Abstract][Full Text] [Related]
11. The Role of Multiparametric Magnetic Resonance Imaging in the Study of Primary Tumor and Pelvic Lymph Node Metastasis in Stage IB1-IIA1 Cervical Cancer.
Zhang X; Dong Y; Song Q; Zhu Y; Pang H; Luo Y; Yu T; Liu F; Guo Y
J Comput Assist Tomogr; 2020; 44(5):750-758. PubMed ID: 32842062
[TBL] [Abstract][Full Text] [Related]
12. Comparison of diffusion kurtosis imaging and dynamic contrast enhanced MRI in prediction of prognostic factors and molecular subtypes in patients with breast cancer.
Wang W; Lv S; Xun J; Wang L; Zhao F; Wang J; Zhou Z; Chen Y; Sun Z; Zhu L
Eur J Radiol; 2022 Sep; 154():110392. PubMed ID: 35679701
[TBL] [Abstract][Full Text] [Related]
13. Combined diffusion-weighted imaging and dynamic contrast-enhanced MRI for differentiating radiologically indeterminate malignant from benign orbital masses.
Xu XQ; Qian W; Ma G; Hu H; Su GY; Liu H; Shi HB; Wu FY
Clin Radiol; 2017 Oct; 72(10):903.e9-903.e15. PubMed ID: 28501096
[TBL] [Abstract][Full Text] [Related]
14. Preoperative histogram parameters of dynamic contrast-enhanced MRI as a potential imaging biomarker for assessing the expression of Ki-67 in prostate cancer.
Zhang Y; Li Z; Gao C; Shen J; Chen M; Liu Y; Cao Z; Pang P; Cui F; Xu M
Cancer Med; 2021 Jul; 10(13):4240-4249. PubMed ID: 34117733
[TBL] [Abstract][Full Text] [Related]
15. Whole-tumour histogram analysis of pharmacokinetic parameters from dynamic contrast-enhanced MRI in resectable oesophageal squamous cell carcinoma can predict T-stage and regional lymph node metastasis.
Chen YL; Li R; Chen TW; Ou J; Zhang XM; Chen F; Wu L; Jiang Y; Laws M; Shah K; Joseph B; Hu J
Eur J Radiol; 2019 Mar; 112():112-120. PubMed ID: 30777199
[TBL] [Abstract][Full Text] [Related]
16. Standard diffusion-weighted, intravoxel incoherent motion, and dynamic contrast-enhanced MRI of musculoskeletal tumours: correlations with Ki67 proliferation status.
Zhan J; Hao D; Wang D; Yue B; Zhou R; Tian N; Liu M; Gao C; Xu W; Cui J
Clin Radiol; 2021 Dec; 76(12):941.e11-941.e18. PubMed ID: 34579866
[TBL] [Abstract][Full Text] [Related]
17. Multiparametric magnetic resonance imaging for the assessment of extracapsular invasion and other staging parameters in patients with prostate cancer candidates for radical prostatectomy.
Lista F; Gimbernat H; Cáceres F; Rodríguez-Barbero JM; Castillo E; Angulo JC
Actas Urol Esp; 2014 Jun; 38(5):290-7. PubMed ID: 24387827
[TBL] [Abstract][Full Text] [Related]
18. Detection of prostate cancer in peripheral zone: comparison of MR diffusion tensor imaging, quantitative dynamic contrast-enhanced MRI, and the two techniques combined at 3.0 T.
Li C; Chen M; Li S; Zhao X; Zhang C; Luo X; Zhou C
Acta Radiol; 2014 Mar; 55(2):239-47. PubMed ID: 23892233
[TBL] [Abstract][Full Text] [Related]
19. Dynamic contrast-enhanced and diffusion-weighted MRI of invasive breast cancer for the prediction of sentinel lymph node status.
Choi EJ; Youk JH; Choi H; Song JS
J Magn Reson Imaging; 2020 Feb; 51(2):615-626. PubMed ID: 31313393
[TBL] [Abstract][Full Text] [Related]
20. Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer.
Li X; Abramson RG; Arlinghaus LR; Kang H; Chakravarthy AB; Abramson VG; Farley J; Mayer IA; Kelley MC; Meszoely IM; Means-Powell J; Grau AM; Sanders M; Yankeelov TE
Invest Radiol; 2015 Apr; 50(4):195-204. PubMed ID: 25360603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
